Section 3 of 6
Product information and disease description
217 evidence topics · 62 sources
Product description
Phase of product development
Summary: development and regulatory status as of November 2026
The FDA approved tiratricol (Emcitate) tablets for oral suspension on 28 September 2026 for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency (Allan-Herndon-Dudley syndrome), with a limitation of use stating that it is not recommended for the treatment of primary hypothyroidism. The approval was granted to Egetis Therapeutics US Inc., and it is the first FDA-approved treatment for MCT8 deficiency. Egetis completed a rolling NDA submission on 29 January 2026, and on 27 March 2026 announced that the FDA had accepted the application with priority review and a PDUFA target action date of 28 September 2026. Tiratricol received orphan drug designation in January 2019, rare pediatric disease designation in November 2020, fast track designation in 2021, and breakthrough therapy designation in 2025, and the FDA granted Egetis a rare pediatric disease priority review voucher in connection with the approval. The prescribing information states that efficacy was evaluated in two studies (NCT05579327 and NCT02060474); Egetis states that the approval was also supported by Triac Trial II, the EMC Cohort Study, the EMC Survival Study, and the U.S. Expanded Access Program. At approval, Egetis expected commercial availability in the United States eight to ten weeks after approval, and on 27 October 2026 it announced U.S. commercial availability. In the European Union, tiratricol was authorised on 12 February 2025 as a hybrid medicine whose reference product is Téatrois, a 0.35 mg tablet authorised in France in 1974, and it was launched in Germany on 1 May 2025. A U.S. composition patent was granted on 5 May 2026, and Egetis expects it to expire in 2045. In Japan, the licensee Fujimoto Pharmaceuticals expects to submit an NDA at the beginning of 2027.
Regulatory status: Approved; NDA submitted January 2026 and approved September 2026
Launch: Launched October 2026
FDA approval on 28 September 2026
| Drug name | Active ingredient | Approval date | FDA-approved use on approval date |
|---|---|---|---|
| “Emcitate” | “tiratricol” | “9/28/2026” | “To treat peripheral thyrotoxicosis in patients with MCT8 deficiency” |
Evidence supporting approval
Expedited programs: priority review and special FDA designations
Rare pediatric disease priority review voucher
Special FDA designations: orphan drug designation
| Field | Quoted record |
|---|---|
| Generic name | “tiratricol” |
| Date designated | “01/16/2019” |
| Orphan designation | “Treatment of Monocarboxylate 8 Transporter (MCT8) Deficiency (Allan-Herndon-Dudley-Syndrome)” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |
| Sponsor | “Rare Thyroid Therapeutics” |
Special FDA designations: Fast Track
Special FDA designations: Breakthrough Therapy
Special FDA designations: Rare Pediatric Disease
Patent protection: U.S. composition patent
Approval and launch outside the United States: European Union authorisation
Approval and launch outside the United States: European Union application and legal basis
| Field | Quoted record |
|---|---|
| Legal basis | “Hybrid application (Article 10(3) of Directive No 2001/83/EC).” |
| Reference product | “Téatrois 0.35 mg tablet” |
| Reference product date of authorisation | “25-06-1974” |
| Reference product Member State | “France” |
Approval and launch outside the United States: launch in Germany
Approval and launch outside the United States: other European countries and Japan
Tiratricol development and approval review
“Tiratricol received its first approval on 12 February 2025 in the European Union, for the treatment of peripheral thyrotoxicosis in patients with MCT8 deficiency (Allan-Herndon-Dudley Syndrome), from birth.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This article summarizes the milestones in the development of tiratricol leading to this first approval for MCT8 deficiency.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Product information
Generic, brand name and therapeutic class of product
Generic name
| Field | Quoted record |
|---|---|
| Name of medicine | “Emcitate” |
| Active substance | “tiratricol” |
| International non-proprietary name (INN) or common name | “tiratricol” |
Manufacturer: Egetis Therapeutics
Therapeutic class: thyroid hormone receptor agonist
Chemical description
Dosage forms and strengths
Tablet for oral suspension: strength and appearance
Package and national drug code
Storage
European Union presentation: dispersible tablet strength
European Union presentation: composition, storage, and pack size
Material safety data sheet
No evidence found.
Average sales price and wholesale acquisition cost
Summary: estimated monthly and annual cost
- Price basis: $74,000 per pack, the price stated by an executive of ANI Pharmaceuticals, which has offered to acquire Egetis Therapeutics, at the Jefferies Global Healthcare Conference on 17 November 2026. No wholesale acquisition cost published by Egetis or in a state price transparency filing was found, so this is a rounded, press-reported list price. The pack is the carton of 60 tablets of 350 mcg (NDC 87216-0100-1), so $74,000 ÷ 60 = $1,233.33 per tablet. Trade press reported a list price of around $950,000 per year at the October 2026 launch.
- Dosing basis: dosage is individualized by body weight, total T3 concentration, and signs of thyrotoxicosis; the mean maintenance dose in Study 2 of the prescribing information was 741 mcg per day. Tablets carry a functional score and can be split into equal halves, with the unused half stored for later use, so cost is computed per tablet used.
- Base case: 741 mcg per day. 741 mcg ÷ 350 mcg = 2.117 tablets per day × $1,233.33 = $2,611.14 per day × 365 days = $953,067 per year; ÷ 12 = $79,422 per month.
- Range: $225,083 per year ($18,757 per month) at 175 mcg per day (half a tablet) to $3,858,571 per year ($321,548 per month) at 3,000 mcg per day: 3,000 mcg ÷ 350 mcg = 8.571 tablets per day × $1,233.33 = $10,571.43 per day × 365 days = $3,858,571 per year; ÷ 12 = $321,548 per month. The 350 mcg per day starting dose for patients weighing more than 10 kg costs $450,167 per year ($37,514 per month).
- Rationale for the range: the lower bound is the starting dose for patients weighing 10 kg or less. The prescribing information reports the Study 1 and Study 2 populations by age and the Study 2 maintenance dose as a mean, and the Study 2 publication and its appendix report doses per kilogram of body weight; no cited source reports the highest body weight or the highest daily dose administered in either study. The upper bound is therefore the maximum recommended dosage for the heaviest weight band the label names, 50 mcg/kg/day for patients weighing 60 kg and above, at the band's threshold of 60 kg. Doses above the upper bound are permitted at two points in the weight scale: the 40 kg to less than 60 kg band allows 60 mcg/kg/day, which approaches 3,600 mcg per day ($4,630,286 per year) just below 60 kg, and the 50 mcg/kg/day maximum reaches 3,600 mcg per day at 72 kg. Titration in 175 mcg or 350 mcg steps about every two weeks to a total T3 target, and dosage reductions of the same size for new or worsening thyrotoxicosis, set each patient's dose, and the first year costs less than later years while the dose is titrated upward. Price is per tablet, so cost is proportional to dose.
- Scope: drug acquisition cost at list price, excluding administration, dispensing, markups, rebates, and patient cost sharing.
Reported U.S. price per pack, November 2026: prospective acquirer at an investor conference
Reported U.S. list price at launch, October 2026: trade press
Product pricing, Germany: pharmacy sales price and statutory rebates
| Packaging size | Costs (pharmacy sales price) | Rebate Section 130 SGB V | Rebate Section 130a SGB V | Costs after deduction of statutory rebates | Price list revision |
|---|---|---|---|---|---|
| “60 TOS” | “€ 15,415.68” | “€ 1.77” | “€ 877.10” | “€ 14,536.81” | “15 August 2025” |
Product pricing, Germany: dose range used for annual treatment costs
| Limit of cost range | Dose per treatment day | Consumption by potency per treatment day | Treatment days per patient per year | Average annual consumption by potency |
|---|---|---|---|---|
| Lower limit | “175 μg” | “0.5 x 350 μg” | “365.0” | “182.5 x 350 μg” |
| Upper limit | “3850 μg” | “11 x 350 μg” | “365.0” | “4015 x 350 μg” |
German reimbursement negotiations: subsequent price agreement
American hospital formulary service (AHFS), or other drug classification
ATC classification
| Field | Quoted record |
|---|---|
| Anatomical therapeutic chemical (ATC) code | “H03AA04” |
| Pharmacotherapeutic group | “Thyroid therapy” |
Indication
U.S. indication and limitation of use
Pharmacology
Mechanism of action
Thyroid hormone receptor agonism independent of MCT8
MCT8-independent cellular entry
MCT8-independent uptake in patient fibroblasts and neural cells
“Fibroblasts from MCT8 patients showed an impaired T3 uptake compared with controls, whereas TA3 uptake was similar in patient and control fibroblasts.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In transfected cells, TA3 did not show significant transport by MCT8.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most importantly, treatment of athyroid Pax8-knockout mice and Mct8/Oatp1c1-double knockout mice between postnatal days 1 and 12 with TA3 restored T3-dependent neural differentiation in the cerebral and cerebellar cortex, indicating that TA3 can replace T3 in promoting brain development.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Thyroid receptor binding
Tiratricol cellular transport
“The aim of the study was to identify transporters that facilitate TRIAC uptake into cells.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We identified SLC22A9 and SLC29A2 as transporters mediating cellular uptake of TRIAC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“SLC22A9 encodes the organic anion transporter 7 (OAT7), a sodium-independent organic anion transporter expressed in the plasma membrane in brain, pituitary, liver, and other organs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“SLC29A2 encodes the equilibrative nucleoside transporter 2 (ENT2), which is ubiquitously expressed, including pituitary and brain.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Knowledge of TRIAC transporter expression patterns, also during brain development, may thus in the future help to interpret observations on TRIAC effects, as well as understand why TRIAC may not show a desirable effect on cells or organs not expressing appropriate transporters.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamics
Concentration-dependent T3 lowering
Exposure-response relationship and TSH suppression
Cardiac electrophysiology
Human cerebral organoid study
Preclinical findings in Mct8/Oatp1c1 double knockout mice
“Here, we directly compared their thyromimetic potential in Mct8/Oatp1c1 double knock-out mice (Dko) modeling human MCT8 deficiency.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dko mice received either Triac (50 ng/g or 400 ng/g) or Ditpa (400 ng/g or 4000 ng/g) daily during the first three postnatal weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Triac treatment (400 ng/g) induced normalized myelination, cortical GABAergic interneuron differentiation, electrophysiological parameters, and locomotor performance only when administered during the first three postnatal weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Together, Triac is highly-effective and more efficient than Ditpa in promoting CNS maturation and function in Dko mice yet needs to be initiated directly after birth for the most beneficial effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Preclinical findings concerning T4 suppression
“The aim of this study was to evaluate the effects and efficacy of therapeutic doses of TRIAC on Mct8-deficient mice (Mct8KO).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Wild-type (Wt) and Mct8KO mice were treated with 30 ng TRIAC/g of body weight/day, given in drinking water, from postnatal day 21 to 30.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“TRIAC treatment greatly decreased plasma T4 in Wt and Mct8KO mice, and reduced T3 to normal levels in the Mct8KO mice.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Therapeutic doses of TRIAC in Mct8KO mice restored plasma T3 levels but severely decreased T4 levels.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The increase in the plasma TRIAC levels after treatment is not sufficient to increase TRIAC levels in the brain and to promote the expression of T3-dependent genes in brain cells. Instead, it leads to a state of brain hypothyroidism with reduced T3 content.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Commentary on the preclinical T4 findings
Pharmacokinetics
Pharmacokinetic parameters: prescribing information
Effect of food: prescribing information
Healthy-volunteer bioequivalence, food-effect, and dose-proportionality study
Population pharmacokinetics in patients and accumulation
Pharmacokinetics: European summary of product characteristics
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Boxed warning: not for treatment of obesity or for weight loss
Contraindication: primary hyperthyroidism
Warning: new onset or worsening of thyrotoxicosis
Warning: laboratory test interference for T3 measurement
Interference with thyroid hormone laboratory measurements
“Varying concentrations (50-1,000 ng/dL) of TRIAC (Sigma Aldrich) were added to pooled serum and assayed for total T3 (TT3) and free T3 (FT3) on the following platforms: e602 (Roche Diagnostics), Architect (Abbott Diagnostics), Centaur (Siemens Healthcare Diagnostics), IMMULITE (Siemens Healthcare Diagnostics), DxI (Beckman Coulter), and Vitros (Ortho Clinical Diagnostics).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Significant overestimation of TT3 and FT3 assays were observed across all platforms corresponding to increasing concentrations of TRIAC. The TRIAC effect at 250 ng/dL showed a constant interference of approximately 190 ng/dL TT3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All commercial TT3 and FT3 assays tested in this work cross-react significantly with TRIAC. Therefore, patients undergoing TRIAC therapy should have T3 hormone response monitored using alternative nonimmunoassay-based methods to avoid misinterpretation of thyroid function profiles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse reactions in more than 5% of participants in Study 1 and Study 2
Common adverse effects in the European regulatory overview
Adverse reactions in the European summary of product characteristics
European Union contraindications and precautions
Nonclinical ophthalmologic findings
Nonclinical toxicology: carcinogenicity, genotoxicity, and fertility
Special populations
Pregnancy restriction: European Union
Pediatric use
Renal and hepatic impairment
Drug/Drug, drug/disease interactions
Effects of other drugs on tiratricol
Drugs that may affect tiratricol absorption
Drugs that may alter plasma binding of T3
| Drug or drug class | Effect | Clinical recommendation |
|---|---|---|
| Oral estrogen-containing products | “These drugs may increase serum thyroxine-binding globulin (TBG) concentration and increase total T3 serum levels.” | “Monitor clinical symptoms and evaluate free T3 levels.” |
| Anabolic steroids and glucocorticoids | “These drugs may decrease serum TBG concentration and decrease total T3 serum levels.” | “Monitor clinical symptoms and evaluate free T3 levels.” |
| Salicylates, more than 2 g/day | “Salicylates inhibit binding of T3 to TBG and transthyretin and may inhibit binding of tiratricol to transthyretin.” | “Monitor clinical symptoms and evaluate free T3 levels.” |
Drugs that may increase hepatic metabolism of tiratricol
| Drug or drug class | Effect | Clinical recommendation |
|---|---|---|
| Drugs that increase hepatic drug-metabolizing enzyme activity | “Administration of drugs that increase hepatic drug-metabolizing enzyme activity may increase the hepatic degradation of thyroid hormones and tiratricol.” | “Serum concentrations of thyroid hormones should be monitored and dose adjustments of EMCITATE considered when initiating, titrating or discontinuing treatment with enzyme inducing agents.” |
Drugs that may affect tiratricol: European summary of product characteristics
Proton pump inhibitors: published management recommendations
Effects of tiratricol on other drugs
In vitro enzyme and transporter inhibition and induction
Effects of tiratricol on other drugs: European summary of product characteristics
Dosing and administration
Dosage
Individualized dosage
Starting dosage, titration increment, and dosage reduction by body weight
| Body weight | Recommended starting dosage | Titration increment | Dosage reduction for new or worsening thyrotoxicosis | Discontinuation taper |
|---|---|---|---|---|
| 10 kg or less | “175 mcg/day” | “175 mcg/day.” | “175 mcg” | “reduce EMCITATE by 175 mcg/day once every two weeks.” |
| Greater than 10 kg | “350 mcg/day” | “350 mcg/day.” | “350 mcg” | “reduce EMCITATE by 350 mcg/day once every two weeks.” |
Maximum recommended dosage by body weight
| Body weight | Maximum recommended dosage |
|---|---|
| Less than 10 kg | “100 mcg/kg/day” |
| 10 kg to less than 40 kg | “80 mcg/kg/day” |
| 40 kg to less than 60 kg | “60 mcg/kg/day” |
| 60 kg and above | “50 mcg/kg/day” |
Dose titration to total T3
Dosage reduction for new or worsening thyrotoxicosis
Missed dose or vomiting
Discontinuation
Starting dose by body weight: published management recommendations
| Body weight | Starting dose |
|---|---|
| Less than 10 kg | “175 µg once daily” |
| 10 kg or greater | “350 µg once daily” |
Maximum daily dose by body weight: published management recommendations
| Body weight | Maximum daily dose |
|---|---|
| Less than 10 kg | “100 µg/kg/day” |
| 10–40 kg | “80 µg/kg/day” |
| 40–60 kg | “60 µg/kg/day” |
| More than 60 kg | “50 µg/kg/day” |
Dose escalation in Triac Trial I
“Triac was administered in a predefined escalating dose schedule-after the initial dose of once-daily 350 μg Triac, the daily dose was increased progressively in 350 μg increments, with the goal of attaining serum total T3 concentrations within the target range of 1·4-2·5 nmol/L.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Maintenance dose in a real-life cohort
“The daily starting dose was based on body weight (175 µg Triac < 10 kg; 350 µg Triac ≥ 10 kg). The daily dose was increased with increments of 175 µg or 350 µg with a goal of attaining serum total T3 concentrations within the target range of 1.4 to 2.5 nmol/L.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean time to reach the maintenance dose was 5.0 (SD 4.7) months, with a mean of 2.7 (SD 1.1) dose increments. The median maintenance dose was 38 µg/kg/day (interquartile range, 31-61 µg/kg/day; range, 15-105 µg/kg/day).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Administration
Daily dosing schedule
Preparation of the oral suspension
Enteral feeding tube administration
Divided dosing: published management recommendations
European Union administration: dispersion volume and feeding tubes
Access and distribution
Specialty pharmacy: PANTHERx Rare
Patient support program: Egetis RareLink
QuickStart, Bridge, patient assistance, and copay programs
Prescription requirements
| Form item | Form text |
|---|---|
| Prescriber attestation | “Prescriber Attestation: I confirm that the patient has been diagnosed with MCT8 deficiency.” |
| Genetic confirmation | “Genetic test result for a mutation in SLC16A2” |
| Copy of genetic test | “Copy of genetic test result included” |
| Baseline thyroid function | “Baseline serum T3 (include units of measurement and date of result)” |
| Prior thyromimetic therapy | “Has the patient ever received DITPA (3,5-diiodothyropropionic acid)?” |
| Prior tiratricol exposure | “Did the patient take EMCITATE® as part of the EAP or clinical trial?” |
| Body weight | “Weight (kg)” |
Distribution and expanded access: U.S. Expanded Access Program
Distribution and expanded access: managed access policy
Co-prescribed/Concomitant therapies
Other thyroid medications
Effect of tiratricol on quality measures
No evidence found.
Product comparison
Comparison with diiodothyropropionic acid: published management recommendations
Comparison with the reference product Téatrois
Place of product in therapy
Disease description
Definition and etiology
Transporter function and loss-of-function mechanism
X-linked inheritance and recurrence risk
Affected females with skewed X-chromosome inactivation
“MCT8 deficiency typically affects males due to its X-linked inheritance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Female patients with heterozygous pathogenic variants in SLC16A2 and skewed X-chromosome inactivation may present with variable neuro(psycho)logical, behavioral, and thyroid function test abnormalities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Epidemiology
Incidence of MCT8 deficiency
Nationwide Japanese epidemiology: incidence
| Measure | Estimate |
|---|---|
| Incidence per million births in Japan, with 95% confidence interval | “2.12 (95 % CI: 0.99–3.25)”View highlighted excerpt for this quote |
Nationwide Japanese epidemiology: survey method and response rate
“In the primary survey, the response rate was 694/1027 (67.6 %), and 31 hospitals had experience in treating patients with MCT8 deficiency. Forty-five patients were genetically diagnosed as MCT8 deficient, and eight were strongly suspected based on the clinical course.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of MCT8 deficiency
Published prevalence estimates
Number of identified patients and families worldwide
Nationwide Japanese epidemiology: prevalence
| Measure | Estimate |
|---|---|
| Estimated prevalence in Japan | “1 in 1,890,000”View highlighted excerpt for this quote |
Nationwide Japanese epidemiology: prevalence calculation
“To estimate the minimum number of patients with MCT8 deficiency patients in Japan, we divided the number of genetically confirmed patients (n = 45) by the questionnaire response rate of the primary survey (67.6 %). Thus, there are approximately 67 MCT8 deficiency patients in Japan.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Stated limitation of the Japanese prevalence estimate
“There is a need for caution regarding the present results. This survey mainly asked questions to pediatric facilities and did not survey adult departments.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“number of adult patients with MCT8 deficiency who are followed by general practitioners may be underestimated.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, the present results should be regarded as minimum estimates.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Natural history, survival, and mortality
International natural-history cohort: design, objective, and population
International natural-history cohort: mortality, causes of death, and overall survival
International natural-history cohort: prognostic factors for death
International natural-history cohort: motor and cognitive abilities with age
Japanese nationwide survey: functional status and deaths
“All patients showed severe psychomotor retardation, and none were able to walk or speak.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Subsequently, 29 surviving and three deceased patients were identified (Fig. 1). The cause and age of death in the three patients were sudden death (4 years), cardiopulmonary arrest after vomiting (35 years), and pneumonia (24 years).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean age of the surviving 29 patients was 12.0 years (range 2.3–31.4) with a median of 9.7 years (three patients over 20 years of age).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Japanese nationwide survey: imaging and neurophysiology over time
Pathophysiology
Central hypothyroidism and chronic peripheral thyrotoxicosis
Tissue-specific thyroid hormone transport and elevated serum T3
Peripheral manifestations and serum markers of thyroid hormone excess
Diagnosis
Guideline recommendations for diagnostic evaluation and SLC16A2 sequencing
“When considering a diagnosis of MCT8 deficiency, we recommend a full clinical assessment to determine whether the patient exhibits any recognized clinical phenotypes and a physical examination, including neurological assessment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If MCT8 deficiency is suspected, we recommend additional investigations including (but not limited to) serum (free) T3, (free) T4, reverse T3 (rT3) and TSH concentrations (interpreting results in the context of age-specific reference intervals)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that SLC16A2 sequencing be performed in any male patient with: the following ‘major criteria’; typical biochemical profile (TSH within normal range or mildly raised, low or low-normal (F)T4, raised (F)T3, low reverse T3, and/or elevated (F)T3/(F)T4 or T3/rT3 ratio) in combination with either global developmental delay, hypomyelination on MRI, clinical signs of movement disorder (e.g. dystonia, bradykinesia), persistent primitive reflexes, or a positive family history for MCT8 deficiency” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Definitive diagnosis of MCT8 deficiency requires identification of a known pathogenic mutation, either by reliable in silico prediction and/or functional studies of novel variants in transfected cells or patient-derived cells.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnostic and genetic criteria
Free T3 to free T4 ratio as a screening biomarker: Japanese nationwide survey
“The significantly higher value of the free T3/free T4 (fT3/fT4) ratio found in our study can be a simple and useful diagnostic biomarker (Our value 11.60 ± 4.14 vs control 3.03 ± 0.38).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We created a receiver operating characteristic (ROC) curve from our data (27 genetically diagnosed cases) and Oto et al.’s data (129 controls) and confirmed that the sensitivity was 96.2 % and the false positive rate was 0 at cutoff values of 4, 4.5 and 5.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Free T3 to free T4 ratio as a screening biomarker: Turkish multicentre cohort
“In this multicenter, retrospective, cross-sectional study, the genetic characteristics and clinical data of twenty-one cases of genetically confirmed MCT8 deficiency were evaluated. The median age at the diagnosis was 2.4 (1.29; 5.9) years, which ranged from 0.5 to 14.0 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In this study, with the exception of three cases with fT3/fT4 ratios of 4.95, 3.58, and 4.52, all cases exhibited fT3/fT4 ratios higher than five (9.9 (7.9; 12.0)).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Free T3 to free T4 ratio threshold in a monitoring guideline
Newborn screening and neonatal biomarkers
Dried blood spot reverse T3 at birth
“Contrary to characteristic iodothyronine abnormalities of MCT8 deficiency during later life, T3 and T4 values were not discriminatory from those of other study groups. In contrast, rT3 was significantly lower.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“rT3 and T3/rT3 ratio in DBS samples obtained from neonates can serve as biomarkers to detect MCT8 deficiency at birth.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnostic delay: international natural-history cohort
Diagnostic delay and alternative diagnoses: international parent registry
“The median reported age of onset of symptoms was 4 months (range, 1-13 months; Supplementary Fig. S5) (11), whereas the median age of diagnosis was 18 months (range, 4-312 months), indicating a median diagnostic delay of 14 months (range, 0-311 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median diagnostic delay was significantly shorter in patients born in or after 2017 vs before 2017 (8 vs 19 months, P < .0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Reported alternative diagnoses (total n = 6) were cerebral palsy (n = 4), Pelizaeus-Merzbacher (like) disease (n = 1) and mitochondrial disease (not otherwise specified, n = 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical presentation - signs and symptoms
Cognitive and developmental symptoms: intellectual disability, walking, and speech
Developmental milestones: Japanese nationwide survey
| Finding | Participants with finding (evaluable denominator in label) |
|---|---|
| Completion of head control, n = 28 | “7 (25 %)”View highlighted excerpt for this quote |
| Able to keep sitting, n = 28 | “0 (0 %)”View highlighted excerpt for this quote |
| Able to speak a word, n = 27 | “0 (0 %)”View highlighted excerpt for this quote |
| Abnormal sleep rhythm, n = 27 | “9 (33 %)”View highlighted excerpt for this quote |
| Feeding difficulty, n = 26 | “4 (15 %)”View highlighted excerpt for this quote |
Motor symptoms: hypotonia, dystonia, and bradykinesia
Motor symptoms: truncal hypotonia and paroxysmal dyskinesias
Seizures
Cardiovascular and nutritional manifestations: international natural-history cohort
| Manifestation | Affected participants and evaluable denominator |
|---|---|
| Elevated systolic blood pressure above the 90th percentile | “25 (53%) of 47” |
| Premature atrial contractions | “34 (76%) of 45” |
| Resting tachycardia | “20 (31%) of 64” |
| Underweight | “59 (71%) of 83” |
Biochemical and neuroimaging findings: international natural-history cohort
Phenotypic spectrum in an exome-sequenced United States cohort
“In a cohort of 122 individuals with SLC16A2 variants, we identified 68 cases with likely pathogenic/pathogenic (L/PATH) variants and 54 individuals with variants of uncertain significance (VUSs).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Common HPO terms included global developmental delay (79/108, 73.1%), generalized hypotonia (40/108, 37.0%), and delayed speech and language development (29/108, 26.9%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“HPO terms related to thyroid function and/or hormone levels were not commonly reported, with hypothyroidism the most frequently reported term, seen in six individuals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term morbidity
Progressive motor complications
Feeding difficulties, undernutrition, and respiratory infection
Burden of MCT8 deficiency
Humanistic burden and health-related quality of life
International parent registry: objective and population
“The primary objective was to document the complex needs and daily care challenges encountered in care for patients with MCT8 deficiency and to what extent these are met by supportive measures and specialist care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 46 registered patients with full informed consent, data of 40 patients (40 males, 100%) with a median age of 3.0 years (range, 0.5-31.6 years), from 18 countries in 5 different continents” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
International parent registry: difficulties in daily care
| Parent-reported difficulty | Participants |
|---|---|
| Feeding | “17 of 33 patients”View highlighted excerpt for this quote |
| Limited motor skills | “12 of 33 patients”View highlighted excerpt for this quote |
| Sleeping problems | “11 of 33 patients”View highlighted excerpt for this quote |
| Mobility | “10 of 33 patients”View highlighted excerpt for this quote |
| Communication | “8 of 33 patients”View highlighted excerpt for this quote |
International parent registry: use of supportive and specialist care
“Despite feeding problems being the most commonly reported difficulty in daily life, only 11 of 36 patients received advice from a professional dietician or nutrologist” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of those with reported feeding problems, only 2 of 16 patients had a feeding tube (data on feeding tube missing for 1 patient).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two of 32 patients were under care of a cardiologist.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The majority of parents (18 of 31 patients) deemed knowledge about MCT8 deficiency among medical professionals as bad or very bad” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
International parent registry: limitations stated by the authors
“First, it is unclear to which extent the patients in this study represent the entire population of patients with MCT8 deficiency.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second, patients deceased before the initiation of the registry were not included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver-reported patient functioning and health-related quality of life
Dependence on caregivers for activities of daily living
“All the patients in this study presented with severe psychomotor retardation. Most were bedridden (a few held their head up) and had no speech. All patients required assistance in all aspects of daily living, including eating and toileting.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
United States real-world cost study: objective, data sources, and population
United States real-world cost study: all-cause costs and utilization
| Measure | Value |
|---|---|
| All-cause cost per patient per year | “$245,393 PPPY” |
United States real-world cost study: clinical drivers of cost
United States real-world cost study: limitations stated by the authors
Economic impact of MCT8 deficiency on families
No evidence found.
Economic impact of diagnostic testing
Access to genetic diagnostics by health system and payer
Financial means as a condition of carrier, prenatal, and preimplantation testing
“As MCT8 deficiency is an inherited condition, carrier testing of at-risk female relatives, prenatal testing for a pregnancy at increased risk, and preimplantation genetic testing are possible, but this is only practicable in families where an affected child has already been born and there are the financial means to pursue this approach” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Approaches to treatment
Current treatment options and standard of care
Thyroid hormone analogues
Guideline recommendations for thyroid hormone analogues
“We recommend treatment with TRIAC (Recommendation: S, Quality of evidence: ØØØO) or DITPA (Recommendation: W, Quality of evidence: ØØOO).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend titrating the dosage of TRIAC (or DITPA), aiming to reduce serum T3 concentrations to a target range between 1.4 and 2.5 nmol/L to alleviate the peripheral thyrotoxic state, unless limited by the occurrence of dose-related side effects” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend long-term therapy with TRIAC (or DITPA) in all patients unless concerns about drug side effects or tolerability arise” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Evidence base for thyroid hormone analogues
“Knowledge of response to thyroxine (alone, or in combination with PTU) and DITPA is limited to case reports and case series, whereas the effects of TRIAC have been studied in a phase 2 clinical trial and a prospective cohort study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment with DITPA (dose range: 2.1–2.5 mg/kg/day) normalized serum T3 and TSH without reduction of T4 concentrations (4/4 cases) and had mixed effects on peripheral symptoms, including a reduction in heart rate (3/4 cases) and improvement in body weight (2/4 cases). Commencement of treatment between 8.5 and 25 months did not improve neurocognitive development” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mechanism and relative evidence for TRIAC and DITPA
Combined levothyroxine and propylthiouracil
Guideline position on levothyroxine monotherapy and on combined levothyroxine and propylthiouracil
“Post-natal treatment with levothyroxine monotherapy is not recommended” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If thyroid hormone analogs are unavailable, we suggest that a combination of levothyroxine and PTU treatment could be considered” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given the rare but potentially severe and life-threatening side effects of PTU and the unknown long-term effects of thyroid hormone analogs, we acknowledge that the risks versus benefits of such therapies should be considered carefully, particularly in patients whose baseline liver function is already deranged” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Published outcomes of levothyroxine alone and with propylthiouracil
“Treatment with levothyroxine in a wide dose range (2.5–15 mcg/kg/day), commenced at the age of 0.5 to 36 months, did not improve neurodevelopment and, in some cases even aggravated the hyperthyroid state in peripheral tissues” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Combination therapy with propylthiouracil (PTU− given to block T4 to T3 conversion) and levothyroxine reduced signs of hyperthyroidism in peripheral tissues in some patients, increasing body weight, reducing heart rate, and serum sex hormone-binding globulin (SHBG) concentrations, but had no beneficial effects on neurocognitive development” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Combined treatment case series: objective and population
“To evaluate the combined administration of propylthiouracil (PTU) and levothyroxine (LT4) in managing monocarboxylate transporter 8 (MCT8) deficiency and identify optimal therapeutic dosages.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This multicenter case series involved 12 male patients with MCT8 deficiency whose parents/guardians consented to PTU and LT4 treatment. Data were collected from January 2008 to June 24, 2024.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At the beginning of treatment, the median age was 18 months (IQR: 9–28 months), and a median of 40 months (IQR: 25–88 months) at the last encounter.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Combined treatment case series: biochemical outcomes
“Patients showed a significant reduction in serum total triiodothyronine (TT3) concentration and TT3/TT4 ratio, with increased serum TT4 and free T4 (fT4) concentrations. The use of PTU effectively reduced TT3 concentration by 25% at an average dose of 6.8 mg/kg/day, while LT4 increased fT4 concentration by 40% from baseline at an average dose of 4.3 µg/kg/day.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Combined treatment with PTU and LT4 normalized serum T3, fT4, and TT4 in patients with MCT8 deficiency.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Combined treatment case series: baseline and last-encounter values
Combined treatment case series: metabolic and physical outcomes
“No statistical differences were observed in metabolic and physical parameters between baseline and last encounter overall for the group, but six of eight patients for whom these data were available had an increase in weight (z-score).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Combined treatment case series: hepatic and hematologic safety
“There were no adverse effects on liver function or granulocyte numbers noted throughout the period of observation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In our limited study, we did not find any evidence of liver toxicity; however, close monitoring of liver function tests is indicated given the concern and the relatively high doses of PTU used.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Combined treatment case series: limitations stated by the authors
“The number of patients in this study is not sufficiently powered to detect significant differences in peripheral tissue markers of TH action due to the variable baseline. Furthermore, the length of treatment was variable. Direct comparisons to other treatments such as DITPA and TRIAC are not possible in this report.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nutritional support and enteral feeding
Guideline recommendations on nutrition and enteral tube feeding
“We recommend careful evaluation of dietary intake to maintain body weight that is adequate for age, and addressing feeding problems to prevent undernutrition. We suggest initiating percutaneous enteral tube feeding and the input of a dietitian to ensure adequate caloric intake at an early stage to prevent malnutrition” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Being underweight in early childhood is associated with higher mortality (104), while caloric intake is frequently inadequate due to impaired swallowing function and increased catabolism due to peripheral tissue thyrotoxicosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Gastrostomy placement and underuse of enteral nutrition
Feeding therapy and tube feeding in severe dysfunction
Symptom-directed neurological pharmacotherapy
Guideline recommendation for symptomatic neurological treatment
“We suggest that all patients should be offered empirical symptomatic treatment for neurological symptoms, including dystonia/hypertonia (spasmolytic drugs), drooling (e.g. anticholinergic drugs), and true epilepsy (carefully distinguished from a paroxysmal movement disorder); and should be referred to rehabilitation physicians/orthopedic surgeons/physiotherapists for measures anticipating contractures, scoliosis, a hip subluxation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the context of MCT8 deficiency, the effectiveness of such interventions has not been evaluated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Symptomatic treatments by manifestation
Rehabilitation and multidisciplinary supportive care
Guideline recommendations for specialist and multidisciplinary care
“We recommend all patients with MCT8 deficiency remain under the care of a (pediatric) endocrinologist and a (pediatric) neurologist” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend the discussion of cases by a multidisciplinary team, comprising (pediatric) endocrinologists, neurologists, cardiologists, dietitians, occupational, speech and physiotherapists, physicians in rehabilitation medicine (physiatrists), orthopedic surgeons, and medical daycare centers” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Supportive treatment and physical therapy
Use of rehabilitation services in an international parent registry
“In line with mobility being an important difficulty in daily life, a majority of 29 of 36 patients received supportive care from a physical therapist” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Further, 18 of 36 patients received therapy on speech and feeding techniques, and 7 of 38 patients used devices to enhance communication (eg, eye tracking devices).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of current therapies
Summary
Available therapies address peripheral thyrotoxicosis and individual symptoms; none has been shown to restore neurodevelopment. The 2024 European Thyroid Association guideline states that no available treatment regimen has rescued the neurocognitive phenotype and that the effectiveness of supportive neurological and gastrointestinal interventions has not been evaluated in MCT8 deficiency. Levothyroxine monotherapy did not improve neurodevelopment and in some cases aggravated peripheral thyrotoxicosis. In Triac Trial II, in participants younger than 30 months at enrollment, tiratricol reduced total serum T3 but did not meet its co-primary GMFM-88 and BSID-III gross motor endpoints compared with natural history scores from Triac Trial I. In a case series of 12 participants receiving combined levothyroxine and propylthiouracil, serum thyroid hormone concentrations normalized, but metabolic and physical parameters did not differ significantly between baseline and the last encounter, and the guideline advises weighing the risk of severe propylthiouracil adverse effects. Supportive care is inconsistently delivered: in an international parent registry, 11 of 36 participants received professional dietary advice and 2 of 16 participants with feeding problems had a feeding tube.
Guideline statement on neurocognitive outcomes and supportive care
“No available treatment regimen has proven to rescue the neurocognitive phenotype in humans with MCT8 deficiency. Patients require supportive/symptomatic treatment of neurological sequelae (i.e. dystonia, spasticity, drooling, scoliosis, feeding problems, epilepsy) and frequently occurring gastrointestinal symptoms (i.e. gastro-esophageal reflux disease, gastroparesis, constipation) according to common practice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Place in treatment, anticipated use, and care setting
Summary
Tiratricol is approved in the United States (September 2026) for peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency and in the EU (February 2025) for peripheral thyrotoxicosis in MCT8 deficiency from birth; it is the first FDA-approved treatment for the disease. The 2024 European Thyroid Association guideline recommends TRIAC (strong recommendation) or DITPA (weak recommendation) with long-term therapy, and suggests combined levothyroxine and propylthiouracil only when thyroid hormone analogues are unavailable. The label advises against combining tiratricol with other thyroid medications such as levothyroxine and propylthiouracil. Dosing is individualized by body weight, total T3 measured by LC-MS/MS, and signs and symptoms of thyrotoxicosis, and the suspension can be given by mouth or through a feeding tube. A 2026 monitoring guideline notes that TRIAC costs substantially more than conventional thyroid hormone preparations and that treatment may be deferred in individual cases, such as patients without biochemical or cardiovascular evidence of thyrotoxicosis. Tiratricol does not replace supportive management of feeding difficulties, developmental disability, spasticity, or movement disorders. In the United States it is dispensed through PANTHERx Rare with the Egetis RareLink support program; before approval, the U.S. Expanded Access Program included 17 hospitals and approximately 60 treated individuals.
Use with other thyroid medications
Cost relative to conventional thyroid hormone preparations
Heterogeneity of treatment effect
Treatment effect by functional impact of the SLC16A2 variant
“In these patients, Triac treatment according a predefined protocol with a median duration of 22.4 (IQR:12.9–42.4) months and a median dose of 40.5 (IQR:28.9–58.0) μg/kg was equally effective in reducing serum T3 concentrations, as well as improving clinical and biochemical outcomes irrespective of the functional impact of the underlying variant, leveraging the potential impact of treatment on thyrotoxic features to all patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We also showed equal effectiveness of the MCT8-independent T3 analogue Triac treatment on different thyrotoxic features across different LoF classifications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment targets by age
“Appropriate treatment targets may vary with age. For example, improved neurodevelopmental outcomes may be the most important goal in neonates but not adults; however, gaining body weight is beneficial to patients of all ages. Attaining these treatment targets may require different therapeutic strategies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phenotypic severity and residual transporter function
Care management intervention strategies
Monitoring guideline: development process and evidence basis
Clinical lead and multidisciplinary coordination
Family support, care coordination, and palliative care
Patient and caregiver counseling on thyrotoxicosis and abrupt discontinuation
Other product development or post-marketing obligations required by the FDA
FDA post-marketing obligations
No evidence found.